Affinity Bio Partners, a global clinical research organization dedicated to safe, ethical studies that ensure subjects benefit from the development of new and novel treatments and therapies, announced that it is launching a clinical study for Pennsylvania's medical cannabis patients suffering from diabetic nerve pain.
“I am thrilled to be working on this clinical study with Dr. Bryan Doner and the Serena Group. The future of medical cannabis and cannabinoids as medical treatments are dependent upon properly performed clinical studies,” says Christina DiArcangelo, CEO of Affinity Bio Partners.
Those who suffer from diabetic nerve pain and are enrolled in Pennsylvania's medical cannabis program can inquire about enrollment by calling 724-859-6200 or emailing research.pgh@serenagroups.com
Más contenido sobre cannabis en Español en El Planteo.
Courtesy photo.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.